Esophageal Cancer: Our Clinical Trials

In addition to providing excellent care, Memorial Sloan Kettering is constantly working to improve treatment for esophageal cancer. Our clinical trials enable us to investigate a variety of new approaches for the diagnosis and treatment of esophageal cancer.

Choosing Memorial Sloan Kettering for your cancer care may offer you access to new therapies that are not widely available elsewhere. Our clinical research team can help determine whether a clinical trial would be right for you, and will work with your esophageal cancer disease management team to ensure that you receive the best possible care. 

Below is a list of clinical trials  that are currently enrolling patients with esophageal cancer at Memorial Sloan Kettering.

Showing 13 trials
Title Investigatorsort icon
A Pilot Trial of PET Imaging with (89)Zr-DFO-Trastuzumab in Esophagogastric Cancer
[Protocol 13-165]
Carrasquillo, Jorge, MD
Coping with Cancer II
[Protocol 14-048]
Epstein, Andrew, MD
A Phase I Study of ADI-PEG 20 plus FOLFOX in Patients with Advanced Digestive Cancers
[Protocol 14-153]
Harding, James, MD
A Phase II Study of Neratinib in Patients with Solid Tumors Containing Mutated HER2
[Protocol 13-140]
Hyman, David, MD
A Phase II Study of PET Scan-Directed Combined Modality Therapy for Esophageal Cancer
[Protocol 12-011]
Ilson, David, MD
A Phase II Study of FOLFOX plus Regorafenib in Patients with Inoperable or Metastatic Esophageal and/or Stomach Cancer
[Protocol 13-080]
Janjigian, Yelena, MD
A Phase II Study of Nintedanib in Patients with Advanced Esophagogastric Cancer
[Protocol 14-094]
Janjigian, Yelena, MD
A Phase II Study of Regorafenib versus Placebo in Patients with Node-Positive Esophageal Cancer Who Completed Chemotherapy, Radiation Therapy, and Surgery
[Protocol 14-169]
Janjigian, Yelena, MD
A Phase II Study of Afatinib (BIBW 2992) in Patients with Advanced HER2-Positive Esophagogastric Cancer Refractory to Trastuzumab
[Protocol 11-166]
Janjigian, Yelena, MD
A Phase II Study of AMG 337 in Patients with Stomach and Esophageal Cancers with High Levels of the MET Protein
[Protocol 13-261]
Ku, Geoffrey, MD
A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Cancer
[Protocol 11-037]
Rizk, Nabil, MD
A Phase II Study of the MatriStem Surgical Matrix to Reinforce the Esophagus in Patients Having Surgery for Gastric and Esophageal Cancer
Newly Diagnosed & Relapsed/Refractory
[Protocol 13-178]
Strong, Vivian, MD
A Phase III Study Evaluating the Addition of Trastuzumab to Standard Therapy for HER2-Positive Esophageal Cancers
[Protocol 12-094]
Wu, Abraham, MD